타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 5개 · 임상 갱신 필요 5개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | zanidatamab (Ziihera, ZW25, zanidatamab-hrii) Jazz Pharmaceuticals / Zymeworks·HER2 (biparatopic) 35 trials | ||||
|---|---|---|---|---|---|
Overview Program | Ziihera (zanidatamab) | TT-00420 | KN046 | KN026 | GQ1001 |
Overview Company | Jazz Pharmaceuticals / Zymeworks | TransThera Sciences (Nanjing), Inc. | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Shanghai JMT-Bio Inc. | GeneQuantum Healthcare (Suzhou) Co., Ltd. |
Overview Modality | ANTIBODY | ANTIBODY | ANTIBODY | ADC | ADC |
Overview Target | HER2 (biparatopic) | HER2 | Colorectal Cancer | Advanced Breast Cancer | HER2 |
Overview Indication | First-line HER2-positive gastric, GEJ, or esophageal adenocarcinoma; previously treated HER2-positive biliary tract cancer | Advanced Solid Tumor; Cholangiocarcinoma | HER2-positive Colorectal Cancer; HER2-positive Biliary Tract Cancer | HER2-positive Colorectal Cancer; HER2-positive Biliary Tract Cancer | HER2-positive Breast Cancer; HER2-positive Biliary Tract Cancer |
Overview Phase | APPROVED | PHASE_2 | PHASE_2 | PHASE_2 | PHASE_1 |
Overview Status | APPROVED | ACTIVE | RECRUITING | RECRUITING | ACTIVE |
Overview Content status | Curated Core | Limited Data | Limited Data | Limited Data | Limited Data |
Overview Data Confidence | Editorial scope · Curated Core | Editorial scope · limited data | Editorial scope · limited data | Editorial scope · limited data | Editorial scope · limited data |
Overview Development Signal | Development Signal · Established | Development Signal · Emerging | Development Signal · Emerging | Development Signal · Emerging | Development Signal · Watch |
Overview Approval status | FDA approved | Investigational | Investigational | Investigational | Investigational |
Positioning Key differentiator | Dual-epitope binding drives receptor clustering, faster internalization, and stronger signaling blockade than either monoclonal alone. In GEA the label splits IHC 3+ (chemo doublet) from IHC 3+ or 2+/ISH+ (chemo + Tevimbra). | — | — | — | — |
Positioning Known limitation | HER2 heterogeneity, PI3K pathway activation, and bypass RTK signaling. | — | — | — | — |
Positioning Development positioning | 1L GEA with fluoropyrimidine-platinum ± Tevimbra; 2L+ BTC monotherapy | — | — | — | — |
MoA Mechanism | Simultaneous binding of two non-overlapping HER2 epitopes crosslinks adjacent receptors, causing receptor clustering, internalization, and degradation alongside ADCC and complement activity. | — | — | — | — |
MoA Biomarker | GEA: PATHWAY 4B5 IHC and VENTANA Dual ISH. IHC 3+ for chemo doublet; IHC 3+ or IHC 2+/ISH+ when Tevimbra is added. BTC: HER2 IHC 3+. | — | — | — | — |
Toxicology Major finding | Embryo-fetal toxicity warning. Diarrhea, infusion-related reactions, and left ventricular dysfunction require monitoring, as with the HER2 antibody class. | — | — | — | — |
Toxicology CRS | N/A | — | — | — | — |
Clinical Safety signal | Embryo-fetal toxicity warning. Diarrhea, infusion-related reactions, and left ventricular dysfunction require monitoring, as with the HER2 antibody class. | — | — | — | — |
Clinical Program phase | APPROVED | PHASE_2 | PHASE_2 | PHASE_2 | PHASE_1 |
Clinical Trial activity | No active/completed counts | — | — | — | — |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 5개 · 임상 갱신 필요 5개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | zanidatamab (Ziihera, ZW25, zanidatamab-hrii) Jazz Pharmaceuticals / Zymeworks·HER2 (biparatopic) 35 trials | ||||
|---|---|---|---|---|---|
Overview Program | Ziihera (zanidatamab) | TT-00420 | KN046 | KN026 | GQ1001 |
Overview Company | Jazz Pharmaceuticals / Zymeworks | TransThera Sciences (Nanjing), Inc. | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Shanghai JMT-Bio Inc. | GeneQuantum Healthcare (Suzhou) Co., Ltd. |
Overview Modality | ANTIBODY | ANTIBODY | ANTIBODY | ADC | ADC |
Overview Target | HER2 (biparatopic) | HER2 | Colorectal Cancer | Advanced Breast Cancer | HER2 |
Overview Indication | First-line HER2-positive gastric, GEJ, or esophageal adenocarcinoma; previously treated HER2-positive biliary tract cancer | Advanced Solid Tumor; Cholangiocarcinoma | HER2-positive Colorectal Cancer; HER2-positive Biliary Tract Cancer | HER2-positive Colorectal Cancer; HER2-positive Biliary Tract Cancer | HER2-positive Breast Cancer; HER2-positive Biliary Tract Cancer |
Overview Phase | APPROVED | PHASE_2 | PHASE_2 | PHASE_2 | PHASE_1 |
Overview Status | APPROVED | ACTIVE | RECRUITING | RECRUITING | ACTIVE |
Overview Content status | Curated Core | Limited Data | Limited Data | Limited Data | Limited Data |
Overview Data Confidence | Editorial scope · Curated Core | Editorial scope · limited data | Editorial scope · limited data | Editorial scope · limited data | Editorial scope · limited data |
Overview Development Signal | Development Signal · Established | Development Signal · Emerging | Development Signal · Emerging | Development Signal · Emerging | Development Signal · Watch |
Overview Approval status | FDA approved | Investigational | Investigational | Investigational | Investigational |
Positioning Key differentiator | Dual-epitope binding drives receptor clustering, faster internalization, and stronger signaling blockade than either monoclonal alone. In GEA the label splits IHC 3+ (chemo doublet) from IHC 3+ or 2+/ISH+ (chemo + Tevimbra). | — | — | — | — |
Positioning Known limitation | HER2 heterogeneity, PI3K pathway activation, and bypass RTK signaling. | — | — | — | — |
Positioning Development positioning | 1L GEA with fluoropyrimidine-platinum ± Tevimbra; 2L+ BTC monotherapy | — | — | — | — |
MoA Mechanism | Simultaneous binding of two non-overlapping HER2 epitopes crosslinks adjacent receptors, causing receptor clustering, internalization, and degradation alongside ADCC and complement activity. | — | — | — | — |
MoA Biomarker | GEA: PATHWAY 4B5 IHC and VENTANA Dual ISH. IHC 3+ for chemo doublet; IHC 3+ or IHC 2+/ISH+ when Tevimbra is added. BTC: HER2 IHC 3+. | — | — | — | — |
Toxicology Major finding | Embryo-fetal toxicity warning. Diarrhea, infusion-related reactions, and left ventricular dysfunction require monitoring, as with the HER2 antibody class. | — | — | — | — |
Toxicology CRS | N/A | — | — | — | — |
Clinical Safety signal | Embryo-fetal toxicity warning. Diarrhea, infusion-related reactions, and left ventricular dysfunction require monitoring, as with the HER2 antibody class. | — | — | — | — |
Clinical Program phase | APPROVED | PHASE_2 | PHASE_2 | PHASE_2 | PHASE_1 |
Clinical Trial activity | No active/completed counts | — | — | — | — |
추천 비교
추천 비교